You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Developing Nanopieces, a Platform RNAi Delivery Technology for Treatment of Multiple Diseases

    SBC: Nanode Therapeutics, Inc.            Topic: NCATS

    STTR_Developing Nanopieces 7. Project Summary/Abstract The bottleneck of developing new RNAi (RNA Interference) drugs is the lack of highly efficient and non-toxic RNA delivery to non-liver tissues in vivo. It is especially challenging to deliver negatively-charged nucleic acid into avascular, dense, and negatively-charged matrix in hard-to-reach tissues including joint cartilage. NanoDe Therapeut ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Pneumococcal conjugate vaccines (PCVs), composed of a pneumococcal polysaccharide covalently linked to a carrier protein, are life-saving prophylactics used to prevent pneumococcal disease. Importantly, PCVs provide immunity for all age groups, including, infants and children under the age of two, which is not the case for purely polysaccharide vaccines. Like all conjugate vaccines ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Expanded Clinical Trial of Granulocyte Colony-Stimulating Factor (G-CSF) to Treat Hot Flush and Other Vasomotor Symptoms in Women with Naturally-Occurring and Surgically-Induced Menopause

    SBC: MENOGENIX, INC.            Topic: NIA

    One of the most common and distressing symptoms of menopause are hot flashes. Hot flashes and related symptoms represent a significant unmet, worldwide, healthcare need, not only in women after surgical or natural menopause, but also in breast and prostate cancer patients undergoing hormone suppression or ablation. Hot flashes occur in 65 – 90% of women undergoing natural menopause and approxima ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Auditory Brain Training to Enhance Satisfaction and Usage of New Hearing Aids by Older Adults

    SBC: customized learning Exercises for Aural Rehabilitation (clEAR) LLC            Topic: R

    Abstract Hearing loss is the third most common health condition for older adults in the US, and if untreated, may lead to social isolation, depression, cognitive decline, and fear of being home alone. Sadly, over 48% of seniors who purchase hearing aids cannot adjust to them well enough to use them daily and 31% report never using them. This is a tragic state of affairs, especailly since a Nationa ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis

    SBC: FIMBRION THERAPEUTICS INC            Topic: NIAID

    Tuberculosis (TB) is caused by infection with the bacterium Mycobacteria tuberculosis (Mtb) and is the leading cause of mortality in the world for a single infectious agent. As efforts to treat TB expand, the prevalence of multidrug resistant TB (MDR-TB), which are resistant to the frontline standard of care (SOC) antibiotics rifampicin and isoniazid, is increasing. Despite the dire need for new t ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. An Improved Intra-Arterial Delivery Platform for Glioblastoma Multiforme

    SBC: UNANDUP, LLC            Topic: 102

    The value of lives lost to cancer-related deaths in the United States is expected to exceed $1.4 trillion by 2020. Of all cancers, glioblastoma multiforme (GBM) is one of the most aggressive types of central nervous system tumors with more than 95% of victims dying within 5 years. Left untreated, median survival is only 3 months. While the incidence rate is 3.2 per 100,000 person-years, GBM is the ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. A High Sensitivity Multiplexed Immunoassay for Aging-Related Inflammation Biomarker Quantification

    SBC: Auragent Bioscience LLC            Topic: NIA

    Abstract Age is the number one risk factor for the major chronic diseases in the developed world. Currently, 81% of adults in the United States are afflicted with one or more chronic diseases. As the average age of the population of the United States continues to grow, we will be faced with a significant disease burden if the percentage of adults with chronic disease remains the same. It is now we ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Light engineering module for fast high-resolution whole-cell imaging

    SBC: Double Helix Optics Inc            Topic: NIBIB

    Summary This Small Business Innovation Research (SBIR) Phase I project is focused on the design, development, and testing of a ground-breaking multidimensional multifunctional quantitative optical microscopy module suitable for live whole cell studies. The module will utilize Light Engineering to achieve fast high-sensitivity, low-noise, high- resolution measurements down to the single-molecule le ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas

    SBC: BIOMIMETIX JV LLC            Topic: NCI

    PROJECT SUMMARY/ABSTRACT A randomized, proof-of-concept, Phase 2 clinical trial of a new class of redox-active pharmaceutical is proposed in 160 subjects undergoing primary treatment for high-grade glioma (WHO grade III and IV). Under a prior Phase II SBIR, a Phase 1 clinical trial has been completed with establishment of the recommended dose being used for this Phase 2 clinical trial. This projec ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Enabling self-reported outcomes for youth with developmental disabilities: The PediatricEvaluation of Disability Inventory- Patient Reported Outcome (PEDI-PRO)- Phase II

    SBC: ABLELINK TECHNOLOGIES INC            Topic: NICHD

    The lack of patient reported outcome measures (PROMs) appropriate for youth with neurodevelopmental disabilities (DD) and related cognitive impairments including Down syndrome (DS) poses a significant problem for healthcare research and practice. Parents and other professionals do not identify the same needs as youth, and failure to engage youth with DD in healthcare evaluation compromises healthc ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government